NVS Quote, Financials, Valuation and Earnings

Monte Rosa Therapeutics has a net margin of 24.21% compared to Novartis AG's net margin of -258.89%. Novartis AG's return on equity of 41.89% beat Monte Rosa Therapeutics's return on equity of --.

Novartis AG has a consensus price target of --, signalling upside risk potential of 15.94%. On the other hand Monte Rosa Therapeutics has an analysts' consensus of -- which suggests that it could grow by 133.03%. Given that Monte Rosa Therapeutics has higher upside potential than Novartis AG, analysts believe Monte Rosa Therapeutics is more attractive than Novartis AG.

Novartis AG has a beta of 0.557, which suggesting that the stock is 44.326% less volatile than S&P 500. In comparison Monte Rosa Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Novartis AG has a quarterly dividend of $3.74 per share corresponding to a yield of 3.8%. Monte Rosa Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 48.86% of its earnings as a dividend. Monte Rosa Therapeutics pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.2B, which are larger than Monte Rosa Therapeutics quarterly revenues of $9.2M. Novartis AG's net income of $3.2B is higher than Monte Rosa Therapeutics's net income of -$23.9M. Notably, Novartis AG's price-to-earnings ratio is 11.53x while Monte Rosa Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.04x versus -- for Monte Rosa Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 24.21% compared to Novartis AG's net margin of 8.48%. Novartis AG's return on equity of 41.89% beat Eli Lilly and's return on equity of 66.4%.

Novartis AG has a consensus price target of --, signalling upside risk potential of 15.94%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 23.68%. Given that Eli Lilly and has higher upside potential than Novartis AG, analysts believe Eli Lilly and is more attractive than Novartis AG.

Novartis AG has a beta of 0.557, which suggesting that the stock is 44.326% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Novartis AG has a quarterly dividend of $3.74 per share corresponding to a yield of 3.8%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.30 per share. Novartis AG pays 48.86% of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.2B, which are larger than Eli Lilly and quarterly revenues of $11.4B. Novartis AG's net income of $3.2B is higher than Eli Lilly and's net income of $970.3M. Notably, Novartis AG's price-to-earnings ratio is 11.53x while Eli Lilly and's PE ratio is 86.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.04x versus 17.61x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 24.21% compared to Novartis AG's net margin of 25.23%. Novartis AG's return on equity of 41.89% beat Pfizer's return on equity of 4.63%.

Novartis AG has a consensus price target of --, signalling upside risk potential of 15.94%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.16%. Given that Pfizer has higher upside potential than Novartis AG, analysts believe Pfizer is more attractive than Novartis AG.

Novartis AG has a beta of 0.557, which suggesting that the stock is 44.326% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Novartis AG has a quarterly dividend of $3.74 per share corresponding to a yield of 3.8%. Pfizer offers a yield of 6.28% to investors and pays a quarterly dividend of $0.42 per share. Novartis AG pays 48.86% of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Novartis AG quarterly revenues are $13.2B, which are smaller than Pfizer quarterly revenues of $17.7B. Novartis AG's net income of $3.2B is lower than Pfizer's net income of $4.5B. Notably, Novartis AG's price-to-earnings ratio is 11.53x while Pfizer's PE ratio is 36.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.04x versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of 24.21% compared to Novartis AG's net margin of -54.2%. Novartis AG's return on equity of 41.89% beat PTC Therapeutics's return on equity of --.

Novartis AG has a consensus price target of --, signalling upside risk potential of 15.94%. On the other hand PTC Therapeutics has an analysts' consensus of -- which suggests that it could grow by 29.47%. Given that PTC Therapeutics has higher upside potential than Novartis AG, analysts believe PTC Therapeutics is more attractive than Novartis AG.

Novartis AG has a beta of 0.557, which suggesting that the stock is 44.326% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.629, suggesting its less volatile than the S&P 500 by 37.101%.

Novartis AG has a quarterly dividend of $3.74 per share corresponding to a yield of 3.8%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 48.86% of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.2B, which are larger than PTC Therapeutics quarterly revenues of $196.8M. Novartis AG's net income of $3.2B is higher than PTC Therapeutics's net income of -$106.7M. Notably, Novartis AG's price-to-earnings ratio is 11.53x while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.04x versus 3.85x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.